Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Executive Summary

Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.

You may also be interested in...



Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience

T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.

Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

Gilead To Let Kite Fly Free; O’Day Says It Will Become Separate Business Unit

On his first earnings call, the new CEO said he wanted to make a quick decision on Kite, which will have its own CEO and autonomy. The unit's Yescarta posted 19% sequential revenue growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099701

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel